![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
The safety and pharmacokinetics of ABI-4334,
a novel next-generation HBV core inhibitor:
Interim results from a Phase 1 study in healthy volunteers
|
|
|
EASL 2023 june 21-24 vienna
Edward J. Gane1, Christian Schwabe2, Jieming Liu3, Luisa M. Stamm3, Kathryn M. Kitrinos3, Steven J. Knox3, Michele Anderson3, Grace Wang3, Katie Zomorodi3
1University of Auckland, Auckland, New Zealand; 2New Zealand Clinical Research, Auckland, New Zealand; 3Assembly Biosciences, Inc., South San Francisco, CA, USA
![0704231](../images/070423/070423-2/0704231.gif)
![0704232](../images/070423/070423-2/0704232.gif)
![0704233](../images/070423/070423-2/0704233.gif)
![0704234](../images/070423/070423-2/0704234.gif)
![0704235](../images/070423/070423-2/0704235.gif)
![0704236](../images/070423/070423-2/0704236.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|